Pfizer to Trial 'TRIPLET' Drug Combo for Cancer Treatment

Source: The Financial Times & Business Finance News

May 10, 2016

Pfizer plans to test a combination of three novel cancer drugs in humans next year, reports David Crow of The Financial Times. With the coming trial, the U.S.-based drugmaker seeks to make up lost ground in the race to develop a new generation of “immunotherapy" medicines.

The three-drug combination will be known as a “TRIPLET” trial and be the first one of its kind in the immuno-oncology segment.

According to Business Finance News, in the beginning, the clinical study is expected to be on a short scale just to ascertain the safety and efficacy profile of the combination drugs.

Reports indicate that, depending on the potential successful trial of the combination therapy, the main factor to consider will be the drug’s cost.

Learn more about the Pfizer announcement from The Financial Times here. 


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments